TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7039761

Group type: EXPERIMENTAL
Intervention: Single 2-g dose of metronidazole
Number of subjects: 163

Group type: COMPARATOR
Intervention: Single 1-g dose of metronidazole
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Retreatment with a single 2-g dose of metronidazole after initial failure
Number of subjects: 163
Study: 31805909

Group type: EXPERIMENTAL
Intervention: Makasi intervention (community-based outreach intervention)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Immediate arm
Number of subjects: 188

Group type: COMPARATOR
Intervention: Deferred arm
Number of subjects: 188
Study: 29692183

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (Group A) from days 1 to 14
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (Group B) from days 15 to 28
Number of subjects: 4
Study: 26508124

Group type: EXPERIMENTAL
Intervention: Inhaled racemic adrenaline
Number of subjects: 363

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: High genomic load of respiratory syncytial virus (RSV)
Number of subjects: 363
Study: 24976291

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 21995882

Group type: EXPERIMENTAL
Intervention: Lidocaine patch (5%)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18807184

Group type: EXPERIMENTAL
Intervention: 7 Fr stent placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 Fr stent placement
Number of subjects: 40
Study: 17547124

Group type: EXPERIMENTAL
Intervention: TMD pain incidence among adolescents
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: TMD pain incidence by age
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: Fluctuating pattern of TMD pain
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: Types of TMD pain cases
Number of subjects: 2255
Study: 15622223

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection followed by surgical deactivation of migraine trigger sites
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 125
Study: 12095066

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 145

Group type: COMPARATOR
Intervention: Adapalene 0.1% gel
Number of subjects: 145
Study: 10740505

Group type: EXPERIMENTAL
Intervention: Left-facing profile images
Number of subjects: 24

Group type: COMPARATOR
Intervention: Right-facing profile images
Number of subjects: 24
Study: 8568113

Group type: EXPERIMENTAL
Intervention: Omeprazole treatment (n = 8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (n = 5)
Number of subjects: 13
Study: 2187310

Group type: COMPARATOR
Intervention: Combination regimen with 0.064% betametason dipropionate ointment (Diprosis) for 1 week before dithranol therapy (B + CSV-therapy)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Conventional dithranol therapy (CSV-therapy)
Number of subjects: 14
Study: 6993085

Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous propranolol
Number of subjects: 24
Study: 30876438

Group type: EXPERIMENTAL
Intervention: High-intensity arm training (three times per week, over three weeks; 60 min each session; total of nine additional sessions)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Low-intensity arm training (same quantity, frequency and treatment time as the intervention group)
Number of subjects: 78
Study: 30082749

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26900895

Group type: EXPERIMENTAL
Intervention: 1-session treatment (OST)
Number of subjects: 83

Group type: COMPARATOR
Intervention: educational support (EST)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 1-session treatment (OST) and educational support (EST)
Number of subjects: 83
Study: 25194168

Group type: EXPERIMENTAL
Intervention: Group of three students per tutor
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Group of five students per tutor
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Group of eight students per tutor
Number of subjects: 74
Study: 22241639

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 400 mg twice a day, n=46
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (usual therapy), n=45
Number of subjects: 91
Study: 20068379

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 0
Study: 17029274

Group type: EXPERIMENTAL
Intervention: Transition Dyspnea Index (TDI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline Dyspnea Index (BDI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI)
Number of subjects: 46
Study: 15175958

Group type: EXPERIMENTAL
Intervention: Protocol treatment (n = 27)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-protocol treatment (n = 14)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy (cumulative dose >/= 400 mg/m2)
Number of subjects: 41
Study: 11182191

Group type: EXPERIMENTAL
Intervention: Trimetazidine (40 mg bolus followed by 60 mg/day intravenously for 48 h)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Trimetazidine and Placebo
Number of subjects: 94
Study: 9638347

Group type: EXPERIMENTAL
Intervention: 200 mg testosterone buciclate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 600 mg testosterone buciclate
Number of subjects: 8
Study: 8074262

Group type: EXPERIMENTAL
Intervention: Turbuhaler (0.5 mg terbutaline x 2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CFC inhaler (0.25 mg terbutaline x 4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: CFC inhaler
Number of subjects: 12
Study: 2478045

Group type: EXPERIMENTAL
Intervention: Paramedian approach
Number of subjects: 49

Group type: COMPARATOR
Intervention: Midline approach
Number of subjects: 49
Study: 974569

Group type: EXPERIMENTAL
Intervention: Well-applied bandages for compression sclerotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical assessment of compression sclerotherapy
Number of subjects: 0
Study: 31027110

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous aerobic exercise (MICAE) 3 times weekly for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional intervention without any physical exercise
Number of subjects: 46
Study: 28428151

Group type: EXPERIMENTAL
Intervention: Traffic-light system (n = 217)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Chilean warning system (n = 225)
Number of subjects: 442
Study: 26581028

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: perphenazine
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 1460
Study: 23779062

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 240 U
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 120 U
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (both doses)
Number of subjects: 219
Study: 22165655

Group type: EXPERIMENTAL
Intervention: Body armor with shorter and thinner collars
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Collars with overlapping segments
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Higher and more rigid collars
Number of subjects: 71
Study: 18849173

Group type: EXPERIMENTAL
Intervention: Glimepiride (1 mg)/Metformin (500 mg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Glibenclamide (5 mg)/Metformin (500 mg)
Number of subjects: 152
Study: 17018657

Group type: EXPERIMENTAL
Intervention: Exercise training (8 weeks)
Number of subjects: 0
Study: 15280527

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 16920315

Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium (MnDPDP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ferucarbotran
Number of subjects: 20
Study: 10553859

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (D10)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg (D5)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg (D2.5)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.25 mg (D1.25)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 150
Study: 8684648

Group type: EXPERIMENTAL
Intervention: Continuous intercostal extrapleural block using bupivacaine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural morphine analgesia
Number of subjects: 0
Study: 1884666

Group type: EXPERIMENTAL
Intervention: Anxiety management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 0
Study: 7121809

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meglumine-Ca-Metrizoate
Number of subjects: 0
Study: 31796013

Group type: EXPERIMENTAL
Intervention: Acoustic reminder and support calls
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual follow-up care (Control)
Number of subjects: 149
Study: 27612486

Group type: EXPERIMENTAL
Intervention: Quality improvement projects to improve communication between providers, workflow design, and chronic disease management.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Work conditions and provider outcomes
Number of subjects: 34
Study: 26932142

Group type: EXPERIMENTAL
Intervention: Preoperative duloxetine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 0
Study: 23592231

Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioral therapy (cCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Session email reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-reminder condition
Number of subjects: 0
Study: 21775122

Group type: EXPERIMENTAL
Intervention: Soy intervention (Daidzein)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 350
Study: 19618811

Group type: EXPERIMENTAL
Intervention: Management-employee group received four one-hour interactive training sessions from a peer educator.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Management only group (control).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received a report outlining deficiencies and prioritizing remediation.
Number of subjects: 40
Study: 17626912

Group type: EXPERIMENTAL
Intervention: Continued fume exposure
Number of subjects: 5724

Group type: EXPERIMENTAL
Intervention: Continued smoking
Number of subjects: 5724

Group type: EXPERIMENTAL
Intervention: Airway hyperresponsiveness
Number of subjects: 5724

Group type: EXPERIMENTAL
Intervention: Dust exposure
Number of subjects: 5724

Group type: EXPERIMENTAL
Intervention: Fume exposure in women
Number of subjects: 5724
Study: 14699463

Group type: EXPERIMENTAL
Intervention: Adequate antibiotic treatment
Number of subjects: 2634

Group type: COMPARATOR
Intervention: Inadequate antibiotic treatment
Number of subjects: 2634
Study: 11156542

Group type: EXPERIMENTAL
Intervention: UVA‐1 cold light treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo light treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: UVA‐1 cold light treatment vs Placebo
Number of subjects: 11
Study: 9683005

Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg i.v.
Number of subjects: 18
Study: 7719089

Group type: EXPERIMENTAL
Intervention: Xiaoyu pian (XYP)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Vitamin C and P and/or adrenosem (Control)
Number of subjects: 137
Study: 31122618

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium scores (CACS) from non-electrocardiogram-gated chest computed tomography (CT)
Number of subjects: 953
Study: 28569454

Group type: EXPERIMENTAL
Intervention: Amoxicillin + Clavulanic acid (2 g/day for 6 days)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Antibiotic + Probiotic (Bifidobacterium longum + lactoferrin)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No antibiotic therapy (Control group)
Number of subjects: 111
Study: 25358635

Group type: EXPERIMENTAL
Intervention: McKenzie training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Classic kinetic exercises (Control)
Number of subjects: 52
Study: 23589506

Group type: EXPERIMENTAL
Intervention: 12-week exercise and health education programme
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 22098700

Group type: EXPERIMENTAL
Intervention: Qigong exercise group (5 times per week for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non‐treated group (maintain current lifestyle)
Number of subjects: 40
Study: 18205033

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16536777

Group type: EXPERIMENTAL
Intervention: Ileal neobladder (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ileocaecal bladder substitution (Group B)
Number of subjects: 60
Study: 12555926

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 42

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 42
Study: 10996387

Group type: EXPERIMENTAL
Intervention: Pentoxiphylline
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 19
Study: 9349846

Group type: EXPERIMENTAL
Intervention: Twice-yearly mebendazole (500 mg)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Thrice-yearly mebendazole (500 mg)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no deworming)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Deworming (general)
Number of subjects: 1000
Study: 8416325

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 3297

Group type: COMPARATOR
Intervention: Control (no beta-blocker therapy)
Number of subjects: 3297
Study: 3709031

Group type: EXPERIMENTAL
Intervention: Cetamolol (46 +/- 21 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetamolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29393233

Group type: EXPERIMENTAL
Intervention: Vitamin D 200 IU/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen or asthma medications
Number of subjects: 80
Study: 25790770

Group type: EXPERIMENTAL
Intervention: 4.5-mm diameter implant (test)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 3.75-mm diameter implant (control)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both implants
Number of subjects: 57
Study: 24037900

Group type: COMPARATOR
Intervention: IPL 0 J/cm²
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IPL 7 J/cm²
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IPL 8 J/cm²
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IPL 10 J/cm²
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: UVR exposure (0 or 8 exposures of 2-4 SED)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All IPL doses
Number of subjects: 21
Study: 23276521

Group type: EXPERIMENTAL
Intervention: Adjuvant 5‐fluorouracil (5‐FU)‐based chemotherapy
Number of subjects: 716

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 716
Study: 19466423

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study: 18467085

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 23
Study: 15983954

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Fenoldopam (without diabetes)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo (without diabetes)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Fenoldopam (postoperative cardiothoracic patients)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo (postoperative cardiothoracic patients)
Number of subjects: 155
Study: 13678932

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 10566571

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 12 weeks (n = 194)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d for 12 weeks (n = 193)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 12 weeks
Number of subjects: 387

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d for 12 weeks
Number of subjects: 387
Study: 9084544

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study: 1816244

Group type: EXPERIMENTAL
Intervention: Partial prophylactic exchange transfusion (continuous flow erythrocytapheresis)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Blood only when serious complications developed (control group)
Number of subjects: 131
Study: 6978111

Group type: EXPERIMENTAL
Intervention: Dopamine at 5.0 micrograms/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dobutamine at 5.0 micrograms/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dobutamine at 7.5 micrograms/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopamine from 5.0 to 7.5 micrograms/kg/min
Number of subjects: 20
Study: 30701815

Group type: EXPERIMENTAL
Intervention: Rectal suppositories containing IFN‐α2b (1 million IU) and antioxidants (alpha‐tocopherol acetate and ascorbic acid) twice a day for 5 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intranasal gel formulation containing IFN‐α2b (36 000 IU/1 g) and antioxidants 3 times a day in addition to rectal suppositories
Number of subjects: 90

Group type: COMPARATOR
Intervention: Umifenovir (reference drug) at a dose of 200 mg 4 times a day for 5 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of rectal and topical dosage forms of IFN‐α2b with antioxidants
Number of subjects: 90
Study: 26645282

Group type: COMPARATOR
Intervention: Supervised training (SUP) - 2/week supervised training, 1/week unsupervised training
Number of subjects: 66

Group type: COMPARATOR
Intervention: Unsupservised training (UNSUP) - 3/week unsupervised training
Number of subjects: 66

Group type: COMPARATOR
Intervention: Passive control group (CON)
Number of subjects: 66
Study: 23506657

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 357
Study: 22898573

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit™ with physiotherapy session
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiotherapy session with lower extremity strengthening and balance training exercises
Number of subjects: 50
Study: 20505654

Group type: EXPERIMENTAL
Intervention: Steroids + Cyclophosphamide
Number of subjects: 54

Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 54
Study: 18284895

Group type: EXPERIMENTAL
Intervention: Access to a befriender facilitator (BF)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 236
Study: 16126373

Group type: EXPERIMENTAL
Intervention: Clotiapine (40 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chlorpromazine (100 mg)
Number of subjects: 58
Study: 14728113

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of SSRIs with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 37
Study: 10997885

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy in PV patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy in ET patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Phlebotomy therapy in PV patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Untreated ET patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Combined groups of PV and ET without myelosuppressive treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CD34+ cells in peripheral blood
Number of subjects: 37
Study: 8987041

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 75
Study: 1479457

Group type: EXPERIMENTAL
Intervention: Continuous negative pressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 30
Study: 3830481

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (non-adenoidectomized children)
Number of subjects: 78
Study: 31533799

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (including cognitive-behavioral therapy, care management, and psychotropic medication consultation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 200
Study: 30365589

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1640
Study: 26797940

Group type: EXPERIMENTAL
Intervention: JASPER parent‐mediated intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Parent psychoeducation intervention
Number of subjects: 85